nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—CYP3A4—bone cancer	0.819	1	CbGaD
Vardenafil—Udenafil—CYP3A4—bone cancer	0.00533	0.667	CrCbGaD
Vardenafil—Sildenafil—CYP3A4—bone cancer	0.00267	0.333	CrCbGaD
Vardenafil—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000672	0.0424	CbGpPWpGaD
Vardenafil—Face oedema—Epirubicin—bone cancer	0.000505	0.00322	CcSEcCtD
Vardenafil—Anaphylactic shock—Cisplatin—bone cancer	0.000501	0.00319	CcSEcCtD
Vardenafil—Infection—Cisplatin—bone cancer	0.000497	0.00317	CcSEcCtD
Vardenafil—Nervous system disorder—Cisplatin—bone cancer	0.000491	0.00313	CcSEcCtD
Vardenafil—Blood creatinine increased—Epirubicin—bone cancer	0.00049	0.00313	CcSEcCtD
Vardenafil—Tachycardia—Cisplatin—bone cancer	0.000489	0.00312	CcSEcCtD
Vardenafil—Skin disorder—Cisplatin—bone cancer	0.000486	0.0031	CcSEcCtD
Vardenafil—Hyperhidrosis—Cisplatin—bone cancer	0.000484	0.00309	CcSEcCtD
Vardenafil—Liver function test abnormal—Epirubicin—bone cancer	0.000483	0.00308	CcSEcCtD
Vardenafil—Orthostatic hypotension—Epirubicin—bone cancer	0.000478	0.00305	CcSEcCtD
Vardenafil—Abdominal pain upper—Epirubicin—bone cancer	0.000478	0.00305	CcSEcCtD
Vardenafil—Breast disorder—Epirubicin—bone cancer	0.000473	0.00302	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000471	0.00301	CcSEcCtD
Vardenafil—Hypotension—Cisplatin—bone cancer	0.000468	0.00298	CcSEcCtD
Vardenafil—Face oedema—Doxorubicin—bone cancer	0.000467	0.00298	CcSEcCtD
Vardenafil—Gastritis—Epirubicin—bone cancer	0.000463	0.00295	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000461	0.00294	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000456	0.00291	CcSEcCtD
Vardenafil—Blood creatinine increased—Doxorubicin—bone cancer	0.000453	0.00289	CcSEcCtD
Vardenafil—Influenza—Epirubicin—bone cancer	0.000452	0.00288	CcSEcCtD
Vardenafil—Dysphagia—Epirubicin—bone cancer	0.000452	0.00288	CcSEcCtD
Vardenafil—Paraesthesia—Cisplatin—bone cancer	0.000449	0.00287	CcSEcCtD
Vardenafil—Liver function test abnormal—Doxorubicin—bone cancer	0.000447	0.00285	CcSEcCtD
Vardenafil—Dyspnoea—Cisplatin—bone cancer	0.000446	0.00285	CcSEcCtD
Vardenafil—Abdominal pain upper—Doxorubicin—bone cancer	0.000442	0.00282	CcSEcCtD
Vardenafil—Orthostatic hypotension—Doxorubicin—bone cancer	0.000442	0.00282	CcSEcCtD
Vardenafil—Photosensitivity reaction—Methotrexate—bone cancer	0.000441	0.00281	CcSEcCtD
Vardenafil—Angina pectoris—Epirubicin—bone cancer	0.00044	0.00281	CcSEcCtD
Vardenafil—Breast disorder—Doxorubicin—bone cancer	0.000437	0.00279	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000436	0.00278	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Cisplatin—bone cancer	0.000432	0.00276	CcSEcCtD
Vardenafil—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000431	0.0272	CbGpPWpGaD
Vardenafil—Infestation NOS—Methotrexate—bone cancer	0.000431	0.00275	CcSEcCtD
Vardenafil—Infestation—Methotrexate—bone cancer	0.000431	0.00275	CcSEcCtD
Vardenafil—Gastritis—Doxorubicin—bone cancer	0.000428	0.00273	CcSEcCtD
Vardenafil—Pain—Cisplatin—bone cancer	0.000428	0.00273	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000427	0.00272	CcSEcCtD
Vardenafil—Conjunctivitis—Methotrexate—bone cancer	0.000419	0.00267	CcSEcCtD
Vardenafil—Influenza—Doxorubicin—bone cancer	0.000418	0.00267	CcSEcCtD
Vardenafil—Dysphagia—Doxorubicin—bone cancer	0.000418	0.00267	CcSEcCtD
Vardenafil—Sweating—Methotrexate—bone cancer	0.000413	0.00263	CcSEcCtD
Vardenafil—Photosensitivity reaction—Epirubicin—bone cancer	0.000413	0.00263	CcSEcCtD
Vardenafil—Feeling abnormal—Cisplatin—bone cancer	0.000413	0.00263	CcSEcCtD
Vardenafil—Haematuria—Methotrexate—bone cancer	0.000411	0.00262	CcSEcCtD
Vardenafil—Angina pectoris—Doxorubicin—bone cancer	0.000407	0.0026	CcSEcCtD
Vardenafil—Hepatobiliary disease—Methotrexate—bone cancer	0.000407	0.0026	CcSEcCtD
Vardenafil—Epistaxis—Methotrexate—bone cancer	0.000406	0.00259	CcSEcCtD
Vardenafil—Infestation NOS—Epirubicin—bone cancer	0.000403	0.00257	CcSEcCtD
Vardenafil—Infestation—Epirubicin—bone cancer	0.000403	0.00257	CcSEcCtD
Vardenafil—Conjunctivitis—Epirubicin—bone cancer	0.000392	0.0025	CcSEcCtD
Vardenafil—Haemoglobin—Methotrexate—bone cancer	0.000389	0.00248	CcSEcCtD
Vardenafil—Haemorrhage—Methotrexate—bone cancer	0.000387	0.00247	CcSEcCtD
Vardenafil—Sweating—Epirubicin—bone cancer	0.000386	0.00247	CcSEcCtD
Vardenafil—Haematuria—Epirubicin—bone cancer	0.000384	0.00245	CcSEcCtD
Vardenafil—Pharyngitis—Methotrexate—bone cancer	0.000384	0.00245	CcSEcCtD
Vardenafil—Urinary tract disorder—Methotrexate—bone cancer	0.000382	0.00244	CcSEcCtD
Vardenafil—Photosensitivity reaction—Doxorubicin—bone cancer	0.000382	0.00244	CcSEcCtD
Vardenafil—Hepatobiliary disease—Epirubicin—bone cancer	0.000381	0.00243	CcSEcCtD
Vardenafil—Epistaxis—Epirubicin—bone cancer	0.00038	0.00243	CcSEcCtD
Vardenafil—Urethral disorder—Methotrexate—bone cancer	0.000379	0.00242	CcSEcCtD
Vardenafil—Sinusitis—Epirubicin—bone cancer	0.000378	0.00241	CcSEcCtD
Vardenafil—Infestation NOS—Doxorubicin—bone cancer	0.000373	0.00238	CcSEcCtD
Vardenafil—Infestation—Doxorubicin—bone cancer	0.000373	0.00238	CcSEcCtD
Vardenafil—Visual impairment—Methotrexate—bone cancer	0.000373	0.00238	CcSEcCtD
Vardenafil—Hypersensitivity—Cisplatin—bone cancer	0.000369	0.00235	CcSEcCtD
Vardenafil—Haemoglobin—Epirubicin—bone cancer	0.000364	0.00232	CcSEcCtD
Vardenafil—Rhinitis—Epirubicin—bone cancer	0.000363	0.00231	CcSEcCtD
Vardenafil—Conjunctivitis—Doxorubicin—bone cancer	0.000363	0.00231	CcSEcCtD
Vardenafil—Haemorrhage—Epirubicin—bone cancer	0.000362	0.00231	CcSEcCtD
Vardenafil—Eye disorder—Methotrexate—bone cancer	0.000361	0.00231	CcSEcCtD
Vardenafil—Tinnitus—Methotrexate—bone cancer	0.00036	0.0023	CcSEcCtD
Vardenafil—Hypoaesthesia—Epirubicin—bone cancer	0.00036	0.0023	CcSEcCtD
Vardenafil—Asthenia—Cisplatin—bone cancer	0.000359	0.00229	CcSEcCtD
Vardenafil—Pharyngitis—Epirubicin—bone cancer	0.000359	0.00229	CcSEcCtD
Vardenafil—Cardiac disorder—Methotrexate—bone cancer	0.000359	0.00229	CcSEcCtD
Vardenafil—Sweating—Doxorubicin—bone cancer	0.000358	0.00228	CcSEcCtD
Vardenafil—Urinary tract disorder—Epirubicin—bone cancer	0.000357	0.00228	CcSEcCtD
Vardenafil—Haematuria—Doxorubicin—bone cancer	0.000356	0.00227	CcSEcCtD
Vardenafil—Connective tissue disorder—Epirubicin—bone cancer	0.000356	0.00227	CcSEcCtD
Vardenafil—Urethral disorder—Epirubicin—bone cancer	0.000355	0.00226	CcSEcCtD
Vardenafil—Hepatobiliary disease—Doxorubicin—bone cancer	0.000353	0.00225	CcSEcCtD
Vardenafil—Epistaxis—Doxorubicin—bone cancer	0.000352	0.00224	CcSEcCtD
Vardenafil—Angiopathy—Methotrexate—bone cancer	0.000351	0.00224	CcSEcCtD
Vardenafil—Sinusitis—Doxorubicin—bone cancer	0.00035	0.00223	CcSEcCtD
Vardenafil—Immune system disorder—Methotrexate—bone cancer	0.000349	0.00223	CcSEcCtD
Vardenafil—Visual impairment—Epirubicin—bone cancer	0.000349	0.00223	CcSEcCtD
Vardenafil—Mediastinal disorder—Methotrexate—bone cancer	0.000348	0.00222	CcSEcCtD
Vardenafil—Diarrhoea—Cisplatin—bone cancer	0.000342	0.00219	CcSEcCtD
Vardenafil—Mental disorder—Methotrexate—bone cancer	0.000339	0.00216	CcSEcCtD
Vardenafil—Eye disorder—Epirubicin—bone cancer	0.000338	0.00216	CcSEcCtD
Vardenafil—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000338	0.0213	CbGpPWpGaD
Vardenafil—Tinnitus—Epirubicin—bone cancer	0.000337	0.00215	CcSEcCtD
Vardenafil—Erythema—Methotrexate—bone cancer	0.000337	0.00215	CcSEcCtD
Vardenafil—Haemoglobin—Doxorubicin—bone cancer	0.000336	0.00215	CcSEcCtD
Vardenafil—Flushing—Epirubicin—bone cancer	0.000336	0.00214	CcSEcCtD
Vardenafil—Cardiac disorder—Epirubicin—bone cancer	0.000336	0.00214	CcSEcCtD
Vardenafil—Rhinitis—Doxorubicin—bone cancer	0.000336	0.00214	CcSEcCtD
Vardenafil—Haemorrhage—Doxorubicin—bone cancer	0.000335	0.00214	CcSEcCtD
Vardenafil—Hypoaesthesia—Doxorubicin—bone cancer	0.000333	0.00213	CcSEcCtD
Vardenafil—Pharyngitis—Doxorubicin—bone cancer	0.000332	0.00212	CcSEcCtD
Vardenafil—Urinary tract disorder—Doxorubicin—bone cancer	0.000331	0.00211	CcSEcCtD
Vardenafil—Connective tissue disorder—Doxorubicin—bone cancer	0.000329	0.0021	CcSEcCtD
Vardenafil—Angiopathy—Epirubicin—bone cancer	0.000328	0.00209	CcSEcCtD
Vardenafil—Urethral disorder—Doxorubicin—bone cancer	0.000328	0.00209	CcSEcCtD
Vardenafil—Immune system disorder—Epirubicin—bone cancer	0.000327	0.00209	CcSEcCtD
Vardenafil—Mediastinal disorder—Epirubicin—bone cancer	0.000326	0.00208	CcSEcCtD
Vardenafil—Back pain—Methotrexate—bone cancer	0.000326	0.00208	CcSEcCtD
Vardenafil—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000324	0.0205	CbGpPWpGaD
Vardenafil—Visual impairment—Doxorubicin—bone cancer	0.000323	0.00206	CcSEcCtD
Vardenafil—Vomiting—Cisplatin—bone cancer	0.000318	0.00203	CcSEcCtD
Vardenafil—Vision blurred—Methotrexate—bone cancer	0.000317	0.00202	CcSEcCtD
Vardenafil—Mental disorder—Epirubicin—bone cancer	0.000317	0.00202	CcSEcCtD
Vardenafil—Rash—Cisplatin—bone cancer	0.000316	0.00201	CcSEcCtD
Vardenafil—Dermatitis—Cisplatin—bone cancer	0.000315	0.00201	CcSEcCtD
Vardenafil—Erythema—Epirubicin—bone cancer	0.000315	0.00201	CcSEcCtD
Vardenafil—Eye disorder—Doxorubicin—bone cancer	0.000313	0.002	CcSEcCtD
Vardenafil—Ill-defined disorder—Methotrexate—bone cancer	0.000312	0.00199	CcSEcCtD
Vardenafil—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000312	0.0197	CbGpPWpGaD
Vardenafil—Tinnitus—Doxorubicin—bone cancer	0.000312	0.00199	CcSEcCtD
Vardenafil—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000312	0.0197	CbGpPWpGaD
Vardenafil—Flushing—Doxorubicin—bone cancer	0.000311	0.00198	CcSEcCtD
Vardenafil—Cardiac disorder—Doxorubicin—bone cancer	0.000311	0.00198	CcSEcCtD
Vardenafil—Back pain—Epirubicin—bone cancer	0.000305	0.00194	CcSEcCtD
Vardenafil—Angiopathy—Doxorubicin—bone cancer	0.000304	0.00194	CcSEcCtD
Vardenafil—Malaise—Methotrexate—bone cancer	0.000304	0.00194	CcSEcCtD
Vardenafil—Muscle spasms—Epirubicin—bone cancer	0.000303	0.00193	CcSEcCtD
Vardenafil—Immune system disorder—Doxorubicin—bone cancer	0.000302	0.00193	CcSEcCtD
Vardenafil—Vertigo—Methotrexate—bone cancer	0.000302	0.00193	CcSEcCtD
Vardenafil—Mediastinal disorder—Doxorubicin—bone cancer	0.000302	0.00193	CcSEcCtD
Vardenafil—Nausea—Cisplatin—bone cancer	0.000297	0.0019	CcSEcCtD
Vardenafil—Vision blurred—Epirubicin—bone cancer	0.000297	0.00189	CcSEcCtD
Vardenafil—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000294	0.0185	CbGpPWpGaD
Vardenafil—Mental disorder—Doxorubicin—bone cancer	0.000293	0.00187	CcSEcCtD
Vardenafil—Ill-defined disorder—Epirubicin—bone cancer	0.000292	0.00186	CcSEcCtD
Vardenafil—Convulsion—Methotrexate—bone cancer	0.000292	0.00186	CcSEcCtD
Vardenafil—Erythema—Doxorubicin—bone cancer	0.000291	0.00186	CcSEcCtD
Vardenafil—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000289	0.0182	CbGpPWpGaD
Vardenafil—Chest pain—Methotrexate—bone cancer	0.000287	0.00183	CcSEcCtD
Vardenafil—Arthralgia—Methotrexate—bone cancer	0.000287	0.00183	CcSEcCtD
Vardenafil—Myalgia—Methotrexate—bone cancer	0.000287	0.00183	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000285	0.00182	CcSEcCtD
Vardenafil—Malaise—Epirubicin—bone cancer	0.000284	0.00181	CcSEcCtD
Vardenafil—Discomfort—Methotrexate—bone cancer	0.000283	0.00181	CcSEcCtD
Vardenafil—Vertigo—Epirubicin—bone cancer	0.000283	0.00181	CcSEcCtD
Vardenafil—Syncope—Epirubicin—bone cancer	0.000282	0.0018	CcSEcCtD
Vardenafil—Back pain—Doxorubicin—bone cancer	0.000282	0.0018	CcSEcCtD
Vardenafil—Muscle spasms—Doxorubicin—bone cancer	0.00028	0.00179	CcSEcCtD
Vardenafil—Palpitations—Epirubicin—bone cancer	0.000278	0.00178	CcSEcCtD
Vardenafil—Loss of consciousness—Epirubicin—bone cancer	0.000277	0.00177	CcSEcCtD
Vardenafil—Anaphylactic shock—Methotrexate—bone cancer	0.000275	0.00175	CcSEcCtD
Vardenafil—Vision blurred—Doxorubicin—bone cancer	0.000275	0.00175	CcSEcCtD
Vardenafil—Convulsion—Epirubicin—bone cancer	0.000273	0.00174	CcSEcCtD
Vardenafil—Infection—Methotrexate—bone cancer	0.000273	0.00174	CcSEcCtD
Vardenafil—Ill-defined disorder—Doxorubicin—bone cancer	0.00027	0.00173	CcSEcCtD
Vardenafil—Nervous system disorder—Methotrexate—bone cancer	0.000269	0.00172	CcSEcCtD
Vardenafil—Arthralgia—Epirubicin—bone cancer	0.000268	0.00171	CcSEcCtD
Vardenafil—Chest pain—Epirubicin—bone cancer	0.000268	0.00171	CcSEcCtD
Vardenafil—Myalgia—Epirubicin—bone cancer	0.000268	0.00171	CcSEcCtD
Vardenafil—Anxiety—Epirubicin—bone cancer	0.000267	0.00171	CcSEcCtD
Vardenafil—Skin disorder—Methotrexate—bone cancer	0.000267	0.0017	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000266	0.0017	CcSEcCtD
Vardenafil—Hyperhidrosis—Methotrexate—bone cancer	0.000266	0.00169	CcSEcCtD
Vardenafil—Discomfort—Epirubicin—bone cancer	0.000265	0.00169	CcSEcCtD
Vardenafil—Malaise—Doxorubicin—bone cancer	0.000263	0.00168	CcSEcCtD
Vardenafil—PDE1B—G Protein Signaling Pathways—GNA11—bone cancer	0.000263	0.0166	CbGpPWpGaD
Vardenafil—Dry mouth—Epirubicin—bone cancer	0.000262	0.00167	CcSEcCtD
Vardenafil—Vertigo—Doxorubicin—bone cancer	0.000262	0.00167	CcSEcCtD
Vardenafil—Syncope—Doxorubicin—bone cancer	0.000261	0.00167	CcSEcCtD
Vardenafil—Palpitations—Doxorubicin—bone cancer	0.000258	0.00164	CcSEcCtD
Vardenafil—Anaphylactic shock—Epirubicin—bone cancer	0.000257	0.00164	CcSEcCtD
Vardenafil—Hypotension—Methotrexate—bone cancer	0.000257	0.00164	CcSEcCtD
Vardenafil—Loss of consciousness—Doxorubicin—bone cancer	0.000256	0.00163	CcSEcCtD
Vardenafil—Infection—Epirubicin—bone cancer	0.000255	0.00163	CcSEcCtD
Vardenafil—Shock—Epirubicin—bone cancer	0.000253	0.00161	CcSEcCtD
Vardenafil—Convulsion—Doxorubicin—bone cancer	0.000253	0.00161	CcSEcCtD
Vardenafil—Nervous system disorder—Epirubicin—bone cancer	0.000252	0.00161	CcSEcCtD
Vardenafil—Tachycardia—Epirubicin—bone cancer	0.000251	0.0016	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00025	0.0016	CcSEcCtD
Vardenafil—Skin disorder—Epirubicin—bone cancer	0.00025	0.00159	CcSEcCtD
Vardenafil—Hyperhidrosis—Epirubicin—bone cancer	0.000249	0.00159	CcSEcCtD
Vardenafil—Insomnia—Methotrexate—bone cancer	0.000248	0.00159	CcSEcCtD
Vardenafil—Chest pain—Doxorubicin—bone cancer	0.000248	0.00158	CcSEcCtD
Vardenafil—Myalgia—Doxorubicin—bone cancer	0.000248	0.00158	CcSEcCtD
Vardenafil—Arthralgia—Doxorubicin—bone cancer	0.000248	0.00158	CcSEcCtD
Vardenafil—Anxiety—Doxorubicin—bone cancer	0.000247	0.00158	CcSEcCtD
Vardenafil—Paraesthesia—Methotrexate—bone cancer	0.000247	0.00157	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000246	0.00157	CcSEcCtD
Vardenafil—Discomfort—Doxorubicin—bone cancer	0.000245	0.00156	CcSEcCtD
Vardenafil—Dyspnoea—Methotrexate—bone cancer	0.000245	0.00156	CcSEcCtD
Vardenafil—Somnolence—Methotrexate—bone cancer	0.000244	0.00156	CcSEcCtD
Vardenafil—Dry mouth—Doxorubicin—bone cancer	0.000243	0.00155	CcSEcCtD
Vardenafil—Dyspepsia—Methotrexate—bone cancer	0.000242	0.00154	CcSEcCtD
Vardenafil—Hypotension—Epirubicin—bone cancer	0.00024	0.00153	CcSEcCtD
Vardenafil—Anaphylactic shock—Doxorubicin—bone cancer	0.000238	0.00152	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Methotrexate—bone cancer	0.000237	0.00151	CcSEcCtD
Vardenafil—Infection—Doxorubicin—bone cancer	0.000236	0.00151	CcSEcCtD
Vardenafil—Pain—Methotrexate—bone cancer	0.000235	0.0015	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000234	0.00149	CcSEcCtD
Vardenafil—Shock—Doxorubicin—bone cancer	0.000234	0.00149	CcSEcCtD
Vardenafil—Nervous system disorder—Doxorubicin—bone cancer	0.000233	0.00149	CcSEcCtD
Vardenafil—Insomnia—Epirubicin—bone cancer	0.000233	0.00148	CcSEcCtD
Vardenafil—Tachycardia—Doxorubicin—bone cancer	0.000232	0.00148	CcSEcCtD
Vardenafil—Skin disorder—Doxorubicin—bone cancer	0.000231	0.00147	CcSEcCtD
Vardenafil—Paraesthesia—Epirubicin—bone cancer	0.000231	0.00147	CcSEcCtD
Vardenafil—Hyperhidrosis—Doxorubicin—bone cancer	0.00023	0.00147	CcSEcCtD
Vardenafil—Dyspnoea—Epirubicin—bone cancer	0.000229	0.00146	CcSEcCtD
Vardenafil—Somnolence—Epirubicin—bone cancer	0.000229	0.00146	CcSEcCtD
Vardenafil—Feeling abnormal—Methotrexate—bone cancer	0.000226	0.00144	CcSEcCtD
Vardenafil—Dyspepsia—Epirubicin—bone cancer	0.000226	0.00144	CcSEcCtD
Vardenafil—Gastrointestinal pain—Methotrexate—bone cancer	0.000225	0.00143	CcSEcCtD
Vardenafil—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000223	0.014	CbGpPWpGaD
Vardenafil—Hypotension—Doxorubicin—bone cancer	0.000222	0.00142	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Epirubicin—bone cancer	0.000222	0.00142	CcSEcCtD
Vardenafil—Pain—Epirubicin—bone cancer	0.00022	0.0014	CcSEcCtD
Vardenafil—Abdominal pain—Methotrexate—bone cancer	0.000217	0.00139	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000217	0.00138	CcSEcCtD
Vardenafil—Insomnia—Doxorubicin—bone cancer	0.000215	0.00137	CcSEcCtD
Vardenafil—Paraesthesia—Doxorubicin—bone cancer	0.000214	0.00136	CcSEcCtD
Vardenafil—Dyspnoea—Doxorubicin—bone cancer	0.000212	0.00135	CcSEcCtD
Vardenafil—Feeling abnormal—Epirubicin—bone cancer	0.000212	0.00135	CcSEcCtD
Vardenafil—Somnolence—Doxorubicin—bone cancer	0.000211	0.00135	CcSEcCtD
Vardenafil—Gastrointestinal pain—Epirubicin—bone cancer	0.00021	0.00134	CcSEcCtD
Vardenafil—Dyspepsia—Doxorubicin—bone cancer	0.000209	0.00134	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000205	0.00131	CcSEcCtD
Vardenafil—Pain—Doxorubicin—bone cancer	0.000203	0.0013	CcSEcCtD
Vardenafil—Abdominal pain—Epirubicin—bone cancer	0.000203	0.0013	CcSEcCtD
Vardenafil—Hypersensitivity—Methotrexate—bone cancer	0.000202	0.00129	CcSEcCtD
Vardenafil—Asthenia—Methotrexate—bone cancer	0.000197	0.00126	CcSEcCtD
Vardenafil—Feeling abnormal—Doxorubicin—bone cancer	0.000196	0.00125	CcSEcCtD
Vardenafil—Gastrointestinal pain—Doxorubicin—bone cancer	0.000194	0.00124	CcSEcCtD
Vardenafil—Pruritus—Methotrexate—bone cancer	0.000194	0.00124	CcSEcCtD
Vardenafil—Hypersensitivity—Epirubicin—bone cancer	0.000189	0.00121	CcSEcCtD
Vardenafil—Abdominal pain—Doxorubicin—bone cancer	0.000188	0.0012	CcSEcCtD
Vardenafil—Diarrhoea—Methotrexate—bone cancer	0.000188	0.0012	CcSEcCtD
Vardenafil—Asthenia—Epirubicin—bone cancer	0.000184	0.00118	CcSEcCtD
Vardenafil—Pruritus—Epirubicin—bone cancer	0.000182	0.00116	CcSEcCtD
Vardenafil—Dizziness—Methotrexate—bone cancer	0.000182	0.00116	CcSEcCtD
Vardenafil—Diarrhoea—Epirubicin—bone cancer	0.000176	0.00112	CcSEcCtD
Vardenafil—Hypersensitivity—Doxorubicin—bone cancer	0.000175	0.00112	CcSEcCtD
Vardenafil—Vomiting—Methotrexate—bone cancer	0.000175	0.00111	CcSEcCtD
Vardenafil—Rash—Methotrexate—bone cancer	0.000173	0.00111	CcSEcCtD
Vardenafil—Dermatitis—Methotrexate—bone cancer	0.000173	0.0011	CcSEcCtD
Vardenafil—Headache—Methotrexate—bone cancer	0.000172	0.0011	CcSEcCtD
Vardenafil—Asthenia—Doxorubicin—bone cancer	0.000171	0.00109	CcSEcCtD
Vardenafil—Dizziness—Epirubicin—bone cancer	0.00017	0.00108	CcSEcCtD
Vardenafil—PDE11A—GPCR downstream signaling—GRM4—bone cancer	0.00017	0.0107	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—RGS1—bone cancer	0.00017	0.0107	CbGpPWpGaD
Vardenafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000169	0.0106	CbGpPWpGaD
Vardenafil—Pruritus—Doxorubicin—bone cancer	0.000168	0.00107	CcSEcCtD
Vardenafil—PDE11A—Hemostasis—SPARC—bone cancer	0.000164	0.0103	CbGpPWpGaD
Vardenafil—Vomiting—Epirubicin—bone cancer	0.000163	0.00104	CcSEcCtD
Vardenafil—PDE1B—EGFR interacts with phospholipase C-gamma—EGFR—bone cancer	0.000163	0.0103	CbGpPWpGaD
Vardenafil—Nausea—Methotrexate—bone cancer	0.000163	0.00104	CcSEcCtD
Vardenafil—Diarrhoea—Doxorubicin—bone cancer	0.000163	0.00104	CcSEcCtD
Vardenafil—Rash—Epirubicin—bone cancer	0.000162	0.00103	CcSEcCtD
Vardenafil—Dermatitis—Epirubicin—bone cancer	0.000162	0.00103	CcSEcCtD
Vardenafil—Headache—Epirubicin—bone cancer	0.000161	0.00103	CcSEcCtD
Vardenafil—PDE1B—PLCG1 events in ERBB2 signaling—EGFR—bone cancer	0.00016	0.0101	CbGpPWpGaD
Vardenafil—Dizziness—Doxorubicin—bone cancer	0.000157	0.001	CcSEcCtD
Vardenafil—PDE11A—Signaling by GPCR—GRM4—bone cancer	0.000154	0.00972	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—RGS1—bone cancer	0.000154	0.00972	CbGpPWpGaD
Vardenafil—Nausea—Epirubicin—bone cancer	0.000153	0.000974	CcSEcCtD
Vardenafil—Vomiting—Doxorubicin—bone cancer	0.000151	0.000965	CcSEcCtD
Vardenafil—PDE10A—GPCR downstream signaling—RGS1—bone cancer	0.000151	0.00954	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—GRM4—bone cancer	0.000151	0.00954	CbGpPWpGaD
Vardenafil—Rash—Doxorubicin—bone cancer	0.00015	0.000957	CcSEcCtD
Vardenafil—PDE11A—Hemostasis—GNA11—bone cancer	0.00015	0.00946	CbGpPWpGaD
Vardenafil—Dermatitis—Doxorubicin—bone cancer	0.00015	0.000956	CcSEcCtD
Vardenafil—Headache—Doxorubicin—bone cancer	0.000149	0.000951	CcSEcCtD
Vardenafil—PDE11A—GPCR downstream signaling—GRM1—bone cancer	0.000147	0.00928	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—SPARC—bone cancer	0.000146	0.00922	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—SPARC—bone cancer	0.000146	0.00922	CbGpPWpGaD
Vardenafil—Nausea—Doxorubicin—bone cancer	0.000141	0.000902	CcSEcCtD
Vardenafil—PDE10A—Signaling by GPCR—RGS1—bone cancer	0.000137	0.00866	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—GRM4—bone cancer	0.000137	0.00866	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—IL3—bone cancer	0.000136	0.00858	CbGpPWpGaD
Vardenafil—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000135	0.0085	CbGpPWpGaD
Vardenafil—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000134	0.00848	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—GNA11—bone cancer	0.000134	0.00843	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—GNA11—bone cancer	0.000134	0.00843	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—GRM1—bone cancer	0.000134	0.00843	CbGpPWpGaD
Vardenafil—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000133	0.00838	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—GRM1—bone cancer	0.000131	0.00827	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—ATF1—bone cancer	0.000129	0.00815	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—IL3—bone cancer	0.000121	0.00765	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—IL3—bone cancer	0.000121	0.00765	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—GRM1—bone cancer	0.000119	0.00751	CbGpPWpGaD
Vardenafil—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000109	0.00689	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—ATF1—bone cancer	9.94e-05	0.00627	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—KIT—bone cancer	9.53e-05	0.00601	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—GNA11—bone cancer	9.47e-05	0.00598	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—SMO—bone cancer	9.41e-05	0.00594	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—RGS1—bone cancer	9.1e-05	0.00574	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—GRM4—bone cancer	9.1e-05	0.00574	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—KIT—bone cancer	8.96e-05	0.00565	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—PLAU—bone cancer	8.92e-05	0.00563	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—KIT—bone cancer	8.91e-05	0.00562	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—KIT—bone cancer	8.87e-05	0.0056	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—KIT—bone cancer	8.82e-05	0.00557	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—GNA11—bone cancer	8.6e-05	0.00543	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—IL3—bone cancer	8.59e-05	0.00542	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—GNA11—bone cancer	8.44e-05	0.00533	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—SMO—bone cancer	8.38e-05	0.00529	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—BRAF—bone cancer	8.38e-05	0.00529	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—RGS1—bone cancer	8.32e-05	0.00525	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—GRM4—bone cancer	8.32e-05	0.00525	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—KIT—bone cancer	8.3e-05	0.00524	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—KIT—bone cancer	8.3e-05	0.00524	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—KIT—bone cancer	8.23e-05	0.00519	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—KIT—bone cancer	8.16e-05	0.00515	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—KIT—bone cancer	8.12e-05	0.00512	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—RGS1—bone cancer	8.11e-05	0.00512	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—GRM4—bone cancer	8.11e-05	0.00512	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—PLAU—bone cancer	7.95e-05	0.00502	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—PLAU—bone cancer	7.95e-05	0.00502	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—GRM1—bone cancer	7.89e-05	0.00498	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—BRAF—bone cancer	7.8e-05	0.00493	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—IL3—bone cancer	7.8e-05	0.00492	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—GNA11—bone cancer	7.67e-05	0.00484	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—GRM4—bone cancer	7.66e-05	0.00483	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—RGS1—bone cancer	7.66e-05	0.00483	CbGpPWpGaD
Vardenafil—PDE6G—Disease—ENO2—bone cancer	7.66e-05	0.00483	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—IL3—bone cancer	7.66e-05	0.00483	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—MDM2—bone cancer	7.5e-05	0.00474	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—SPARC—bone cancer	7.4e-05	0.00467	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	7.35e-05	0.00464	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—GRM1—bone cancer	7.21e-05	0.00455	CbGpPWpGaD
Vardenafil—PDE6G—Disease—DHFR—bone cancer	7.1e-05	0.00448	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—MDM2—bone cancer	7.05e-05	0.00445	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—GRM1—bone cancer	7.03e-05	0.00444	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—MDM2—bone cancer	7.02e-05	0.00443	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—MDM2—bone cancer	6.98e-05	0.00441	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—RGS1—bone cancer	6.96e-05	0.00439	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—GRM4—bone cancer	6.96e-05	0.00439	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—IL3—bone cancer	6.95e-05	0.00439	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—MDM2—bone cancer	6.95e-05	0.00439	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	6.91e-05	0.00436	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—GNA11—bone cancer	6.77e-05	0.00427	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—GRM1—bone cancer	6.64e-05	0.00419	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—MDM2—bone cancer	6.54e-05	0.00413	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—MDM2—bone cancer	6.54e-05	0.00413	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—MDM2—bone cancer	6.48e-05	0.00409	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—MDM2—bone cancer	6.42e-05	0.00405	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—MDM2—bone cancer	6.39e-05	0.00404	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—IL3—bone cancer	6.14e-05	0.00388	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—GRM1—bone cancer	6.03e-05	0.00381	CbGpPWpGaD
Vardenafil—CYP3A5—Biological oxidations—CYP3A4—bone cancer	5.8e-05	0.00366	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	5.79e-05	0.00366	CbGpPWpGaD
Vardenafil—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	5.72e-05	0.00361	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—ATF1—bone cancer	5.67e-05	0.00358	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—KIT—bone cancer	5.66e-05	0.00357	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—SMO—bone cancer	5.56e-05	0.00351	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—BRAF—bone cancer	5.32e-05	0.00336	CbGpPWpGaD
Vardenafil—PDE6G—Disease—TGFBR2—bone cancer	5.15e-05	0.00325	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—EGFR—bone cancer	5.13e-05	0.00324	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—GNA11—bone cancer	5.08e-05	0.00321	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—SMO—bone cancer	5.08e-05	0.00321	CbGpPWpGaD
Vardenafil—CYP3A5—Biological oxidations—GSTP1—bone cancer	4.96e-05	0.00313	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—SMO—bone cancer	4.95e-05	0.00313	CbGpPWpGaD
Vardenafil—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	4.89e-05	0.00309	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—EGFR—bone cancer	4.82e-05	0.00304	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—EGFR—bone cancer	4.8e-05	0.00303	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—EGFR—bone cancer	4.77e-05	0.00301	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—EGFR—bone cancer	4.75e-05	0.003	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—ATF1—bone cancer	4.73e-05	0.00298	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—GNA11—bone cancer	4.65e-05	0.00293	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IL3—bone cancer	4.61e-05	0.00291	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—GNA11—bone cancer	4.53e-05	0.00286	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—EGFR—bone cancer	4.47e-05	0.00282	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—EGFR—bone cancer	4.47e-05	0.00282	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—MDM2—bone cancer	4.45e-05	0.00281	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—EGFR—bone cancer	4.43e-05	0.00279	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—EGFR—bone cancer	4.39e-05	0.00277	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—EGFR—bone cancer	4.37e-05	0.00276	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—ATF1—bone cancer	4.32e-05	0.00273	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—GNA11—bone cancer	4.28e-05	0.0027	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—SMO—bone cancer	4.25e-05	0.00268	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IL3—bone cancer	4.21e-05	0.00266	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—ATF1—bone cancer	4.21e-05	0.00266	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—GRM4—bone cancer	4.11e-05	0.00259	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—RGS1—bone cancer	4.11e-05	0.00259	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IL3—bone cancer	4.11e-05	0.00259	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—PLAU—bone cancer	4.03e-05	0.00254	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	3.96e-05	0.0025	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TGFBR2—bone cancer	3.94e-05	0.00249	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—GNA11—bone cancer	3.89e-05	0.00245	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—IL3—bone cancer	3.88e-05	0.00245	CbGpPWpGaD
Vardenafil—PDE1B—Disease—ENO2—bone cancer	3.78e-05	0.00239	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IGF1R—bone cancer	3.71e-05	0.00234	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TGFBR2—bone cancer	3.6e-05	0.00227	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—TP53—bone cancer	3.58e-05	0.00226	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—GRM1—bone cancer	3.56e-05	0.00225	CbGpPWpGaD
Vardenafil—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.56e-05	0.00225	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—IL3—bone cancer	3.52e-05	0.00222	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TGFBR2—bone cancer	3.51e-05	0.00222	CbGpPWpGaD
Vardenafil—PDE6G—Disease—KIT—bone cancer	3.51e-05	0.00222	CbGpPWpGaD
Vardenafil—PDE1B—Disease—DHFR—bone cancer	3.51e-05	0.00221	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—NDUFA12—bone cancer	3.47e-05	0.00219	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IGF1R—bone cancer	3.39e-05	0.00214	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IGF1R—bone cancer	3.3e-05	0.00209	CbGpPWpGaD
Vardenafil—PDE6G—Disease—BRAF—bone cancer	3.3e-05	0.00208	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—ATF1—bone cancer	3.3e-05	0.00208	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—KIT—bone cancer	3.23e-05	0.00204	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IL3—bone cancer	3.22e-05	0.00203	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—TP53—bone cancer	3.19e-05	0.00202	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—TP53—bone cancer	3.19e-05	0.00202	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—EGFR—bone cancer	3.04e-05	0.00192	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—NT5C3A—bone cancer	2.88e-05	0.00182	CbGpPWpGaD
Vardenafil—PDE6G—Disease—MDM2—bone cancer	2.77e-05	0.00175	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KIT—bone cancer	2.69e-05	0.0017	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PTGS2—bone cancer	2.67e-05	0.00168	CbGpPWpGaD
Vardenafil—PDE1B—Disease—TGFBR2—bone cancer	2.54e-05	0.0016	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—MDM2—bone cancer	2.54e-05	0.0016	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—BRAF—bone cancer	2.53e-05	0.0016	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SMO—bone cancer	2.51e-05	0.00158	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KIT—bone cancer	2.46e-05	0.00155	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—EGFR—bone cancer	2.45e-05	0.00155	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KIT—bone cancer	2.4e-05	0.00151	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—BRAF—bone cancer	2.31e-05	0.00146	CbGpPWpGaD
Vardenafil—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.3e-05	0.00145	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—GNA11—bone cancer	2.3e-05	0.00145	CbGpPWpGaD
Vardenafil—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.27e-05	0.00143	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—BRAF—bone cancer	2.25e-05	0.00142	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—JUN—bone cancer	2.21e-05	0.00139	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—EGFR—bone cancer	2.18e-05	0.00138	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ATF1—bone cancer	2.13e-05	0.00135	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MDM2—bone cancer	2.12e-05	0.00134	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IL3—bone cancer	2.08e-05	0.00131	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MDM2—bone cancer	1.94e-05	0.00122	CbGpPWpGaD
Vardenafil—PDE6G—Disease—EGFR—bone cancer	1.89e-05	0.00119	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MDM2—bone cancer	1.89e-05	0.00119	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KIT—bone cancer	1.88e-05	0.00119	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—JUN—bone cancer	1.84e-05	0.00116	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MMP9—bone cancer	1.79e-05	0.00113	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TGFBR2—bone cancer	1.78e-05	0.00112	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—EGFR—bone cancer	1.74e-05	0.0011	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KIT—bone cancer	1.73e-05	0.00109	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—JUN—bone cancer	1.68e-05	0.00106	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IGF1R—bone cancer	1.67e-05	0.00106	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—JUN—bone cancer	1.64e-05	0.00104	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MMP9—bone cancer	1.64e-05	0.00103	CbGpPWpGaD
Vardenafil—PDE1B—Disease—BRAF—bone cancer	1.63e-05	0.00103	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TP53—bone cancer	1.62e-05	0.00102	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—NDUFA12—bone cancer	1.62e-05	0.00102	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MMP9—bone cancer	1.6e-05	0.00101	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—MDM2—bone cancer	1.48e-05	0.000934	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—EGFR—bone cancer	1.45e-05	0.000913	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MDM2—bone cancer	1.37e-05	0.000862	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—NT5C3A—bone cancer	1.34e-05	0.000845	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—EGFR—bone cancer	1.32e-05	0.000835	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTGS2—bone cancer	1.32e-05	0.000831	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—EGFR—bone cancer	1.29e-05	0.000814	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—JUN—bone cancer	1.29e-05	0.000812	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ENO2—bone cancer	1.26e-05	0.000796	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TP53—bone cancer	1.22e-05	0.000767	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KIT—bone cancer	1.21e-05	0.000767	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—DHFR—bone cancer	1.17e-05	0.000738	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—BRAF—bone cancer	1.14e-05	0.000721	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TP53—bone cancer	1.11e-05	0.000701	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—EGFR—bone cancer	1.11e-05	0.000699	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GNA11—bone cancer	1.09e-05	0.00069	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TP53—bone cancer	1.08e-05	0.000684	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—EGFR—bone cancer	1.01e-05	0.000638	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CYP3A4—bone cancer	9.91e-06	0.000626	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MDM2—bone cancer	9.57e-06	0.000604	CbGpPWpGaD
Vardenafil—PDE1B—Disease—EGFR—bone cancer	9.34e-06	0.000589	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GSTP1—bone cancer	8.48e-06	0.000535	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—JUN—bone cancer	8.32e-06	0.000525	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MMP9—bone cancer	8.09e-06	0.000511	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—EGFR—bone cancer	6.54e-06	0.000413	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ENO2—bone cancer	5.86e-06	0.00037	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TP53—bone cancer	5.49e-06	0.000346	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—DHFR—bone cancer	5.44e-06	0.000343	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GNA11—bone cancer	5.08e-06	0.000321	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTGS2—bone cancer	4.39e-06	0.000277	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GSTP1—bone cancer	3.94e-06	0.000249	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTGS2—bone cancer	2.04e-06	0.000129	CbGpPWpGaD
